Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

(Reuters) - Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Both groups followed a reduced-calorie diet and exercise plan. Common side effects ... found in Mounjaro. While Zepbound is FDA-approved for weight loss, Mounjaro is approved for managing type ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

to plan ahead for this year. Lilly's Zepbound and Novo's Wegovy dominate a market for weight-loss treatments that analysts estimate could be a $150 billion market by the early 2030s. Both the ...

About 140,400 obese patients in Massachusetts were prescribed medications such as Wegovy and Zepbound in 2024 ... As it turns out, her plan excludes payment for weight-loss drugs.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

MORGANTOWN – WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...